Cost Effectiveness of a Potential Vaccine for Human papillomavirus

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Sanders, Gillian D. ; Taira, Al V.
• Description:
  Human papillomavirus (HPV) infection, usually a sexually transmitted disease, is a risk factor for cervical cancer. Given the substantial disease and death associated with HPV and cervical cancer, development of a prophylactic HPV vaccine is a public health priority. We evaluated the cost-effectiveness of vaccinating adolescent girls for high-risk HPV infections relative to current practice. A vaccine with a 75% probability of immunity against high-risk HPV infection resulted in a life-expectancy gain of 2.8 days or 4.0 quality-adjusted life days at a cost of $246 relative to current practice (incremental cost effectiveness of $22,755/quality-adjusted life year [QALY]). If all 12-year-old girls currently living in the United States were vaccinated, >1,300 deaths from cervical cancer would be averted during their lifetimes. Vaccination of girls against high-risk HPV is relatively cost effective even when vaccine efficacy is low. If the vaccine efficacy rate is 35%, the cost effectiveness increases to $52,398/QALY. Although gains in life expectancy may be modest at the individual level, population benefits are substantial.
• Subjects:
  Child Cost-Benefit Analysis Female Humans Markov Chains Models, Theoretical Papillomaviridae Papillomavirus Infections Papillomavirus Vaccines Quality-Adjusted Life Years Quality Of Life Risk Factors Uterine Cervical Neoplasms Vaccination Viral Vaccines

  More +
• Source:
  Emerg Infect Dis. 9(1):37-48.
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Location:
  North America
• Volume:
  9
• Issue:
  1
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:b4d68de86396081beb79fe56219107855fa5c83a838b37f10108c9e46a4d3a8d
• Download URL:
  https://stacks.cdc.gov/view/cdc/13970/cdc_13970_DS1.pdf
• File Type:
  [PDF - 389.46 KB ]